Search research articles
Contact Us
Filters
Showing results (71-80 of 110) with videos related to
Page
of 11
Sort By:
Hepatology (Baltimore, Md.)
|
October 19, 2011
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
Stefan Zeuzem, Peter Buggisch, Kosh Agarwal, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
November 13, 2024
Recompensation of Liver Cirrhosis by TIPS Reduces Epithelial Cell Death Markers, Translating Into Improved Clinical Outcome
Felix Piecha, Beatrice-Victoria Jahn, Johannes Köntopf, et al.
Gastroenterology
|
April 19, 2006
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
Thomas Berg, Michael von Wagner, Samer Nasser, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 16, 2025
Metabolic Dysfunction-Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus Panel
Yestle Kim, Peter Rydqvist, Thomas Ramezani, et al.
Frontiers in Oncology
|
January 1, 2026
What can claims data tell us about risk factors and survival of patients with hepatocellular carcinoma? Insights from a German population-based study
Selina Becht, Najib Ben Khaled, Simone Schrodi, et al.
Zeitschrift Fur Gastroenterologie
|
March 24, 2026
Life-style factors of patients with metabolic dysfunction-associated steatotic liver disease - Data from the German SLD-Registry
Andreas Geier, Martin A Kabelitz, Monika Rau, et al.
Plos One
|
February 12, 2014
Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients
Georgios Grammatikos, Christian Lange, Simone Susser, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
May 29, 2019
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection
Patrick Marcellin, David K Wong, William Sievert, et al.
BMC Gastroenterology
|
February 12, 2017
Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection
Stefan Bourgeois, Hans Van Vlierberghe, Christophe Moreno, et al.
Journal of Affective Disorders
|
June 25, 2021
Influence of gender on cytokine induced depression and treatment: Gender aspects of IFN-α-induced depression
Susanne Sarkar, Jonas Kemper, Rahul Sarkar, et al.
Page
of 11
Search research articles
Search
Showing results (71-80 of 110) with videos related to
Sort By:
Page
of 11
Hepatology (Baltimore, Md.)
|
October 19, 2011
The protease inhibitor, GS-9256, and non-nucleoside polymerase inhibitor tegobuvir alone, with ribavirin, or pegylated interferon plus ribavirin in hepatitis C
Stefan Zeuzem, Peter Buggisch, Kosh Agarwal, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
November 13, 2024
Recompensation of Liver Cirrhosis by TIPS Reduces Epithelial Cell Death Markers, Translating Into Improved Clinical Outcome
Felix Piecha, Beatrice-Victoria Jahn, Johannes Köntopf, et al.
Gastroenterology
|
April 19, 2006
Extended treatment duration for hepatitis C virus type 1: comparing 48 versus 72 weeks of peginterferon-alfa-2a plus ribavirin
Thomas Berg, Michael von Wagner, Samer Nasser, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
July 16, 2025
Metabolic Dysfunction-Associated Steatohepatitis Diagnosis and Management in Germany: Insights From an Expert Consensus Panel
Yestle Kim, Peter Rydqvist, Thomas Ramezani, et al.
Frontiers in Oncology
|
January 1, 2026
What can claims data tell us about risk factors and survival of patients with hepatocellular carcinoma? Insights from a German population-based study
Selina Becht, Najib Ben Khaled, Simone Schrodi, et al.
Zeitschrift Fur Gastroenterologie
|
March 24, 2026
Life-style factors of patients with metabolic dysfunction-associated steatotic liver disease - Data from the German SLD-Registry
Andreas Geier, Martin A Kabelitz, Monika Rau, et al.
Plos One
|
February 12, 2014
Vitamin D levels vary during antiviral treatment but are unable to predict treatment outcome in HCV genotype 1 infected patients
Georgios Grammatikos, Christian Lange, Simone Susser, et al.
Liver International : Official Journal of the International Association for the Study of the Liver
|
May 29, 2019
Ten-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B virus infection
Patrick Marcellin, David K Wong, William Sievert, et al.
BMC Gastroenterology
|
February 12, 2017
Efficacy, safety and pharmacokinetics of simeprevir and TMC647055/ritonavir with or without ribavirin and JNJ-56914845 in HCV genotype 1 infection
Stefan Bourgeois, Hans Van Vlierberghe, Christophe Moreno, et al.
Journal of Affective Disorders
|
June 25, 2021
Influence of gender on cytokine induced depression and treatment: Gender aspects of IFN-α-induced depression
Susanne Sarkar, Jonas Kemper, Rahul Sarkar, et al.
Page
of 11